J Clin Oncol 2011 Jan 10
Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.
Related Questions
Does the answer vary based on whether it is neo/adjuvant or metastatic setting?
New answer by Medical Oncologist at Mayo Clinic Rochester (December 5, 2018)
The nuanced answer would be attuned to receptors, disease status (e.g. non-metastatic vs metastatic) and schedule.In the adjuvant setting, defining studies include E1199 (Spar...